Jan 18, 2014 Health Policy Summit 2014 On the Frontier of the Future for Japan and the World
date : 11/29/2013
Health Policy Summit 2014
On the Frontier of the Future for Japan and the World
On the Frontier of the Future for Japan and the World
■Summary
With the 2013 House of Councillors election putting an end to the so-called “twisted Diet” and a period of stable government under the Liberal Democratic Party and its allies now set for the foreseeable future, health and healthcare policy in Japan once again stands at a major turning point. Faced by the need for integrated reform of the taxation and social security systems and the possibility of new entrants to the healthcare field arising from the TPP agreement, the Abe administration released its Healthcare and Medical Strategy in June 2013. This identified healthcare as a strategic industry and prioritized such issues as creation of a Japanese version of the National Institutes of Health (NIH), globalization of healthcare, stem cell technology including iPS cells, and the use of ICT in the medical field. However, neither the case for prioritizing these issues nor the practical details of any specific measures have been made clear to the public. Moreover, importance has been attached to the globalization of healthcare, and development of a new model of international cooperation is anticipated, but how Japan will position itself in the global context remains unclear. At this year’s Summit, in addition to a comprehensive discussion about the health and healthcare policy of the current administration, we attempted to define Japan’s standing in the international community in the field of health and healthcare in order to clarify the frontier toward which stakeholder can advance in order to build a strong future for Japan.
■Date and Venue
Saturday, January 18, 2014 Hotel New Otani
■Prospective participants
Approximately 100 individuals drawn from among ruling and opposition legislators, ministry officials, healthcare professionals, executives of healthcare-related companies, health policy experts, representatives of major media outlets, journalists, etc.
■Sponsors
Ministry of Foreign Affairs; Ministry of Health, Labour and Welfare; Reconstruction Agency; Ministry of Education, Culture, Sports, Science and Technology
■Cooperated by
National Graduate Institute for Policy Studies, Global Health Innovation Policy Program
■Program (*Speakers are subjective to change.)
10:00-10:20 Opening Remarks
-Kiyoshi Kurokawa (Chairman, Health and Global Policy Institute)
10:20-11:50 Session 1 Key Points of the Abe Administration’s Health Policy
Given the potential long-term stability of the present administration, does its health policy represent the best available options for the country and the optimal allocation of limited financial resources? This session will involve a comprehensive discussion of the key points for success or failure, and the major challenges in promoting these measures.
-Yuuji Kanda (Councilor for Health Insurance, Health Policy, and Cordination between Health Care and Long-term Care, Minister’s Secretariat, Ministry of Health, Labour and Welfare)
-Koji Shinkawa (Budget Examiner for Health, Labour and Welfare, Budget Bureau, Ministry of Finance)
-Takeo Sekihara (Board Member, Japan Cancer Society)
-Ryozo Nagai (President, Jichi Medical University; Member of the National Council on Social Security System Reform)
-Toshio Miyata (Executive Director, Health and Global Policy Institute) (Moderator)
12:10-13:30 Session 2 (Lunch) Healthcare as a Driver of Economic Growth
According to the government’s Health & Healthcare Strategy, the healthcare field is to be promoted as a strategic industry, and in addition to contributing to economic growth, the aim is for the solutions Japan has pioneered to be disseminated worldwide to provide a new model for coping with a super-aging society. In addition, creation of a Japanese NIH as a focal point for health and medical research, globalization of healthcare, exploitation of stem cell technology including iPS cells, and use of ICT in the health and medical field have all been identified as priority issues, but what are the key factors in promoting these areas in practical terms? Moreover, in what specific ways, either directly or indirectly, can the health and healthcare field contribute to economic growth? This session will focus on discussion of the ideal approaches to implementing and promoting these measures.
–Mitsuru Izumo (President, euglena Co., Ltd)
-Takeo Sekihara (Board Member, Japan Cancer Society)
-Ryozo Nagai (President, Jichi Medical University; Member of the National Council on Social Security System Reform)
-Toshio Miyata (Executive Director, Health and Global Policy Institute) (Moderator)
12:10-13:30 Session 2 (Lunch) Healthcare as a Driver of Economic Growth
According to the government’s Health & Healthcare Strategy, the healthcare field is to be promoted as a strategic industry, and in addition to contributing to economic growth, the aim is for the solutions Japan has pioneered to be disseminated worldwide to provide a new model for coping with a super-aging society. In addition, creation of a Japanese NIH as a focal point for health and medical research, globalization of healthcare, exploitation of stem cell technology including iPS cells, and use of ICT in the health and medical field have all been identified as priority issues, but what are the key factors in promoting these areas in practical terms? Moreover, in what specific ways, either directly or indirectly, can the health and healthcare field contribute to economic growth? This session will focus on discussion of the ideal approaches to implementing and promoting these measures.
–Mitsuru Izumo (President, euglena Co., Ltd)
-Yuji Kuroiwa (Governor of Kanagawa Prefecture)
-Rami Suzuki (Group Officer, Executive Director of Eisai Business Development, Eisai Co., Ltd.)
-Rami Suzuki (Group Officer, Executive Director of Eisai Business Development, Eisai Co., Ltd.)
-Yutaka Hishiyama (Councillor, Cabinet Secretariat)
13:45-15:05 【GHIT Fund Sponsored Session】
The global expansion of healthcare is a priority in the government’s Health & Healthcare Strategy. Health also figures prominently in Japan’s new “soft diplomacy” strategy paper. By building mutually beneficial relationships across stakeholders and countries in the health field, Japan can diversify its economic and diplomatic means for international cooperation, and contribute to positive health outcomes for partner countries. In what areas can Japan best contribute, through what types of innovative action, and what represents the ideal model for international cooperation? In this session, we will seek to clarify how and what types of “push” and “pull” strategies can be used to increase Japan’s contribution of its innovations in the global context.
-Eriko Asai (Managing Director, Government Affairs and Policy, GE Japan)
15:20-16:40 Session 4 On The Frontier of Japan’s Future
Discussion thus far has made clear the healthcare issues that Japan must resolve and the role it must play in the international community. In this session, in summing up the day’s discussions, we will ask where the frontier lies that each stakeholder can advance towards right now in order to open up a new future for Japan. Through discussion with panelists active in various fields, we hope to clarify where these frontiers lie.
-Hiromitsu Tazawa (Senior Executive officer, Miraca Holdings Inc.)
-Yasuchika Hasegawa(President & CEO, Takeda Pharmaceutical Company Limited)
-Kohei Onozaki (Former director general of the Health and Global Policy Institute) (Moderator)
13:45-15:05 【GHIT Fund Sponsored Session】
Session 3 Healthcare Innovation
& Global Contribution: Japan’s Role in the International Community
The global expansion of healthcare is a priority in the government’s Health & Healthcare Strategy. Health also figures prominently in Japan’s new “soft diplomacy” strategy paper. By building mutually beneficial relationships across stakeholders and countries in the health field, Japan can diversify its economic and diplomatic means for international cooperation, and contribute to positive health outcomes for partner countries. In what areas can Japan best contribute, through what types of innovative action, and what represents the ideal model for international cooperation? In this session, we will seek to clarify how and what types of “push” and “pull” strategies can be used to increase Japan’s contribution of its innovations in the global context.
-Eriko Asai (Managing Director, Government Affairs and Policy, GE Japan)
-Shiro Konuma (Director, Global Health Policy Division, International Cooperation Bureau, Ministry of Foreign Affairs)
-BT Slingsby (CEO, Global Health Innovative Technology Fund)
-Steve Morrison (Senior Vice President and Director, Global Health Policy Center, CSIS)
-Alex Ross (Director, WHO Centre for Health Development) (Moderator)
-Alex Ross (Director, WHO Centre for Health Development) (Moderator)
15:20-16:40 Session 4 On The Frontier of Japan’s Future
Discussion thus far has made clear the healthcare issues that Japan must resolve and the role it must play in the international community. In this session, in summing up the day’s discussions, we will ask where the frontier lies that each stakeholder can advance towards right now in order to open up a new future for Japan. Through discussion with panelists active in various fields, we hope to clarify where these frontiers lie.
-Hiromitsu Tazawa (Senior Executive officer, Miraca Holdings Inc.)
-Yasuchika Hasegawa(President & CEO, Takeda Pharmaceutical Company Limited)
-Hirofumi Hirano (Chief Executive Officer–Japan, KKR Japan Limited)
-Atsuko Muraki (Vice Minister, Ministry of Health, Labour and Welfare)
-Tadayuki Tamai (Assistant managing editor & Editorial Writer, Yomiuri Shimbun) (Moderator)
16:40-16:50 Closing Remarks
-Kiyoshi Kurokawa (Chairman, Health and Global Policy Institute)
17:00-18:30 Reception
*Simultaneous translation will be provided.
■Secretariat
Health and Global Policy Institute（Oyamada・Kubota）
TEL: 03-5511-8521 FAX: 03-5511-8523
Email: info@hgpi.org Normal 0 0 2 false false false EN-US JA X-NONE /* Style Definitions */ table.MsoNormalTable {mso-style-name:標準の表; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-qformat:yes; mso-style-parent:””; mso-padding-alt:0mm 5.4pt 0mm 5.4pt; mso-para-margin:0mm; mso-para-margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:10.5pt; mso-bidi-font-size:11.0pt; font-family:”Century”,”serif”; mso-ascii-font-family:Century; mso-ascii-theme-font:minor-latin; mso-hansi-font-family:Century; mso-hansi-theme-font:minor-latin; mso-font-kerning:1.0pt;}
-Tadayuki Tamai (Assistant managing editor & Editorial Writer, Yomiuri Shimbun) (Moderator)
16:40-16:50 Closing Remarks
-Kiyoshi Kurokawa (Chairman, Health and Global Policy Institute)
17:00-18:30 Reception
*Simultaneous translation will be provided.
■Secretariat
Health and Global Policy Institute（Oyamada・Kubota）
TEL: 03-5511-8521 FAX: 03-5511-8523
Email: info@hgpi.org Normal 0 0 2 false false false EN-US JA X-NONE /* Style Definitions */ table.MsoNormalTable {mso-style-name:標準の表; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-qformat:yes; mso-style-parent:””; mso-padding-alt:0mm 5.4pt 0mm 5.4pt; mso-para-margin:0mm; mso-para-margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:10.5pt; mso-bidi-font-size:11.0pt; font-family:”Century”,”serif”; mso-ascii-font-family:Century; mso-ascii-theme-font:minor-latin; mso-hansi-font-family:Century; mso-hansi-theme-font:minor-latin; mso-font-kerning:1.0pt;}
Registration deadline: 2014-01-08
Exhibition date：2014-01-18
Top Research & Recommendations Posts
- [Policy Recommendations] Developing a National Health and Climate Strategy for Japan (June 26, 2024)
- [Research Report] The 2023 Public Opinion Survey on Satisfaction in Healthcare in Japan and Healthcare Applications of Generative AI (January 11, 2024)
- [Policy Recommendations] Integrating Climate and Health for a Sustainable Society: Incorporating a Planetary Health Perspective into Nationally Determined Contributions (NDCs)(December 9, 2024)
- [Research Report] Survey of Japanese Nursing Professionals Regarding Climate Change and Health (Final Version) (November 14, 2024)
- [Policy Recommendations] Obesity Control Promotion Project 2023 “The Next Steps for Engaging and Cooperating with Patients, Citizens, and Communities for Implements of Obesity Control Measurements” (April 8, 2024)
- [Announcement] A Turning Point Towards Building Green Healthcare Systems (June 5, 2024)
- [Research Report] Building a Mental Health Program for Children and Measuring its Effectiveness (June 16, 2022）
- [Event Report] Planetary Health Expert Meeting Aiming for Sustainable Healthcare: Learning from the Impact of Environmental Pollution and Medical Waste During the Pandemic (February 16, 2024)
- [Policy Recommendations] The Women’s Health Promotion Project “Policy proposal for Promotion of Menopausal Women’s Health as a Social Issue to be Considered by Industry, Government, Academia and the Private Sector” (July 31, 2024)
- [Reserch Report] Antimicrobial Resistance (AMR) Measures in Sweden (November 21, 2024)
Featured Posts
-
2024-11-25
[Registration Open] (Webinar) The 130th HGPI Seminar “Marking a Decade of the Act on Medical Care for Patients With Intractable Diseases: Connecting Intractable Diseases and Society From the Perspective of a Media Professional and Family Member” (January 28, 2025)
![[Registration Open] (Webinar) The 130th HGPI Seminar “Marking a Decade of the Act on Medical Care for Patients With Intractable Diseases: Connecting Intractable Diseases and Society From the Perspective of a Media Professional and Family Member” (January 28, 2025)](https://hgpi.org/en/wp-content/uploads/sites/2/hs130-top_JPNENG-1.png)
-
2024-11-29
[Registration Open] (Webinar) The 129th HGPI Seminar “The Connection Between Planetary Environment and Human Health as Seen Through the JECS and Future Expectations” (December 23, 2024)
![[Registration Open] (Webinar) The 129th HGPI Seminar “The Connection Between Planetary Environment and Human Health as Seen Through the JECS and Future Expectations” (December 23, 2024)](https://hgpi.org/en/wp-content/uploads/sites/2/hs129-top.png)
-
2024-12-09
[Policy Recommendations] Integrating Climate and Health for a Sustainable Society: Incorporating a Planetary Health Perspective into Nationally Determined Contributions (NDCs)(December 9, 2024)
![[Policy Recommendations] Integrating Climate and Health for a Sustainable Society: Incorporating a Planetary Health Perspective into Nationally Determined Contributions (NDCs)(December 9, 2024)](https://hgpi.org/en/wp-content/uploads/sites/2/160f1c0c260ce6021440137773571fc9.png)
-
2024-12-12
[HGPI Policy Column] (No. 51) From the Planetary Health Project “Part 11: Efforts Toward Achieving Carbon Neutrality in Japan’s Pharmaceutical Industry”
![[HGPI Policy Column] (No. 51) From the Planetary Health Project “Part 11: Efforts Toward Achieving Carbon Neutrality in Japan’s Pharmaceutical Industry”](https://hgpi.org/en/wp-content/uploads/sites/2/HGPI_20241206_PolicyColumn_eyecatch.png)
-
2024-12-18
[Policy Recommendations] Policy Recommendations on Strengthening CKD Strategies for Workers: The Importance of Providing Early Detection, Intervention, and Support Through Screenings and Medical Visits (October 28, 2024)
![[Policy Recommendations] Policy Recommendations on Strengthening CKD Strategies for Workers: The Importance of Providing Early Detection, Intervention, and Support Through Screenings and Medical Visits (October 28, 2024)](https://hgpi.org/en/wp-content/uploads/sites/2/HGPI_20241023_FY2024CKD_eyecatch.jpg)
